Patients suffering from Membranous nephropathy, disorder of kidney, can be effectively treated with Rituximab. The finding was revealed in the April 2009 print issue of the Clinical Journal of the American Society of Nephrology (CJASN).
Currently, treatment options for Membranous nephropathy are limited to calcineurin inhibitors, steroids, and chemotherapeutic agents, all of which have some side effects.
Andrew Bomback, MD (University of North Carolina Kidney Center), and his colleagues after conducting the first systematic review of rituximab use in patients with membranous nephropathy compared the effect of rituximab therapy for treating patients struggling against nephropathy.
From News-Medical.Net:
To investigate rituximab’s potential, Andrew Bomback, MD (University of North Carolina Kidney Center), and his colleagues conducted the first systematic review of rituximab use in patients with membranous nephropathy. They collected and analyzed all of the data available on rituximab therapy in this patient population. They found 21 articles to date, all of which were either case reports or case series without controls, meaning that patients taking rituximab were studied for a certain length of time but were not compared with patients not taking the drug.
Dr. Bomback remarked that future studies would decide the value of Rituximab and this drug must only be used in research settings till that time.
If you would like to make a comment, please fill out the form below.
